Anemia and Reduced Kidney Function as Risk Factors for New Onset of Atrial Fibrillation (from the Ibaraki Prefectural Health Study)

Xu, DongZhu; Murakoshi, Nobuyuki; Sairenchi, Toshimi; Irie, Fujiko; Igarashi, Miyako; Nogami, Akihiko; Tomizawa, Takuji; Yamaguchi, Iwao; Yamagishi, Kazumasa; Iso, Hiroyasu; Ota, Hitoshi; Aonuma, Kazutaka

doi:10.1016/j.amjcard.2014.10.041

Cited by 53 publications

(49 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In a population-based cohort study, Xu et al [13] reported anemia and reduced renal functions as risk factors for NOAF. However, studies investigating the relationship between admission laboratory parameters and NOAF are limited.…”

Section: Discussionmentioning

confidence: 98%

Association of admission serum laboratory parameters with new-onset atrial fibrillation after a primary percutaneous coronary intervention

Karataş

Çanga

İpek

et al. 2016

Coronary Artery Disease

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 98%

Association of admission serum laboratory parameters with new-onset atrial fibrillation after a primary percutaneous coronary intervention

Karataş

Çanga

İpek

et al. 2016

Coronary Artery Disease

View full text Add to dashboard Cite

show abstract

“…Anemia is known as an independent factor for new onset of AF and is associated with adverse cardiovascular outcomes [13]. The role of these factors was established in previous studies [1,3].…”

Section: Discussionmentioning

confidence: 99%

“…On the other hand, the risk of new-onset AF is raised in patients with CKD [12]. In the Ibaraki Prefectural Health Study, it was shown that CKD in combination with anemia is synergistically associated with a higher risk for AF onset [13]. It is estimated that 19-24% of the patients with CKD are diagnosed with AF [14,15].…”

Section: Discussionmentioning

confidence: 99%

Matrix Metalloproteinase Neutrophil Gelatinase-Associated Lipocalin Complex Predicts Atrial Fibrillation Recurrence after Electrical Cardioversion in Obese Patients

et al. 2016

View full text Add to dashboard Cite

Background: There is not much data on matrix metalloproteinase neutrophil gelatinase-associated lipocalin (MMP-NGAL) complex in patients with atrial fibrillation (AF). Aim: The aim of the study was to assess the value of MMP-NGAL complex in predicting AF recurrence after electrical cardioversion. Methods: The serum levels of NGAL, cystatin C, interleukin-6, high-sensitivity C-reactive protein, copeptin, MMP-NGAL complex, matrix metalloproteinase 2, tissue inhibitor of metalloproteinase 1, Von Willebrand factor, B-type natriuretic peptide and the urinary level of NGAL were evaluated before cardioversion. Results: A total of 83 patients with persistent AF were enrolled in the study. Left atrial diameter (LA) ≥4.5 cm was significantly associated with AF recurrence at follow-up (p = 0.009). In selected 39 obese patients, MMP-NGAL complex was associated with AF recurrence (p = 0.03). If the concentration of MMP-NGAL complex increased by 1 ng/ml, the odds of AF recurrence increased by 4% (OR 1.04; CI: 1.00-1.08; p = 0.03). MMP-NGAL complex did not correlate with AF recurrence in patients with a first episode of AF, in patients ≥65 years of age and in patients with a LA ≥4.5 cm or with chronic kidney disease. Conclusions: It is known that the greater the BMI at baseline, the higher the likelihood of progression from paroxysmal to permanent AF. However, European Society of Cardiology (ESC) guidelines do not consider obese patients a population with a low likelihood of success of cardioversion. That is why we need a sensitive marker to predict sinus rhythm maintenance in such a population. We found that MMP-NGAL complex may predict AF recurrence after successful cardioversion in obese patients.

show abstract

“…гда почечная недостаточность сочетается с другими ге-риатрическими симптомами, в частности, с анемией [33]. С другой стороны, анемия является фактором рис-ка развития кровотечения у больных ФП и ассоцииру-ется с увеличением смертности [34].…”

Section: Antithrombotic Therapy In Elderly Patients With Atrial Fibriunclassified

Approaches to Antithrombotic Therapy in Elderly Patients With Atrial Fibrillation

Ушкалова

Zyryanov

Dumchenko

2017

Racionalʹnaâ farmakoterapiâ v kardiologii

View full text Add to dashboard Cite

Российский университет дружбы народов. Россия 117198, Москва, ул. Миклухо-Маклая, 6Пожилой возраст -наиболее важный и независимый фактор риска развития фибрилляции предсердий (ФП). Доля больных с ФП в воз-расте 65-85 лет достигает 70%, а средний возраст пациентов с ФП составляет 75 лет. Антитромботическая терапия у пожилых затруднена в силу ряда причин. С одной стороны, у пожилых повышен риск развития системной эмболии и инсульта, а также фатальных исходов ин-сульта по сравнению с более молодыми пациентами. С другой стороны, у пожилых пациентов повышен риск кровотечений. Кроме того, они страдают сопутствующими заболеваниями и получают препараты, которые могут вступать во взаимодействия с антитромботическими сред-ствами. В статье обсуждаются шкалы, применяемые для оценки риска тромбоэмболических и геморрагических осложнений и общие под-ходы к антитромботической терапии у пожилых пациентов. Advanced age is the most important and independent risk factor for the development of atrial fibrillation (AF). The proportion of patients with AF at the age of 65-85 years reaches 70%, and average age of patients with AF is 75 years. Antithrombotic therapy of AF in the elderly is challenging for several reasons. On the one hand, elderly patients are at an increased risk of systemic embolism and stroke and fatal outcomes of stroke are higher in the elderly compared with these in the younger patients. On the other hand, elderlies are at an increased risk of bleeding. In addition, they have important comorbidities and are treated with drugs that can interact with antithrombotic agents. The article discusses tools used to assess risks of thromboembolic and hemorrhagic complications and general approaches to antithrombotic treatment of elderly patients.Keywords: antithrombotic therapy, atrial fibrillation, elderly, assessment of risk of thromboembolic and hemorrhagic complications. АКТУАЛЬНЫЕ ВОПРОСЫ КЛИНИЧЕСКОЙ ФАРМАКОЛОГИИ ВведениеФибрилляция предсердий (ФП) -самый часто встречающийся вид сердечной аритмии, распростра-ненность которой значительно увеличивается с воз-растом. Согласно данным эпидемиологических ис-следований у лиц старше 80 лет она достигает 15-20% по сравнению с <0,1% у лиц моложе 40 лет [1,2]. Воз-можно, что реальная распространенность ФП еще выше, так как методы, применяемые в эпидемиологи-ческих исследованиях, недостаточно выявляют паро-ксизмальную форму ФП [3].По данным Фремингемского исследования рас-пространенность и частота ФП удваиваются каждое де-сятилетие после 50 лет [4]. Например, среди мужчин 75-79 лет распространенность ФП в 2 раза превыша-ет таковую среди мужчин в возрасте 65-69 лет и в 5 раз -в возрасте 55-59 лет [5]. Доля лиц 65-85 лет среди пациентов c ФП достигает 70%, а средний возраст боль-ных составляет 75 лет [6,7]. В связи с постарением на-селения встречаемость ФП продолжает расти -если в 1990 г. она составляла в мире 60,7 на 100000 чело-веко-лет среди мужчин и 43,8 -среди женщин, то в

show abstract

Anemia and Reduced Kidney Function as Risk Factors for New Onset of Atrial Fibrillation (from the Ibaraki Prefectural Health Study)

Cited by 53 publications

References 22 publications

Association of admission serum laboratory parameters with new-onset atrial fibrillation after a primary percutaneous coronary intervention

Association of admission serum laboratory parameters with new-onset atrial fibrillation after a primary percutaneous coronary intervention

Matrix Metalloproteinase Neutrophil Gelatinase-Associated Lipocalin Complex Predicts Atrial Fibrillation Recurrence after Electrical Cardioversion in Obese Patients

Approaches to Antithrombotic Therapy in Elderly Patients With Atrial Fibrillation

Contact Info

Product

Resources

About